請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72917
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳學良(Hsueh-Liang Wu) | |
dc.contributor.author | Siang-Jin Lin | en |
dc.contributor.author | 林湘瑾 | zh_TW |
dc.date.accessioned | 2021-06-17T07:10:17Z | - |
dc.date.available | 2024-07-23 | |
dc.date.copyright | 2019-07-23 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-22 | |
dc.identifier.citation | 一、中文部分
Browne, M. N. & Keeley, S. M.著;羅耀宗,蔡宏明,黃賓星譯(2019),看穿假象、理智發聲,從問對問題開始:[全球長銷40年]美國大學邏輯思辨聖經。台北:城邦商業周刊。 Reeves, M. , Haanaes, K.& Sinha, J.著;王喆,韓陽譯(2017),策略選擇;掌握解決問題的過程,面對複雜多變的挑戰。台北:經濟新潮社。 克雷 等著;李田樹譯(2002),哈佛商業評論精選23:合併與收購。台北:天下遠見出版股份有限公司。 潘家涓(2017),生醫產業策略性併購的四大關鍵,環球生技月刊。 袁照晶(2005),生技醫藥業之創新授權合作與鑑價模式。國立台灣大學碩士論文。 孫智麗(2015),無形資產鑑價-生物科技研發成果評價方法與案例。台灣經濟研究院生醫創新與商業化課程講義。 陳盈蓁(2018),跨國併購面面觀-交易架構之選擇,勤業眾信通訊。 陳盈蓁 (2017),生醫併購法律議題不可忽視,勤業眾信通訊。 勤業眾信聯合會計師事務所(2018),2018生技產業合作交易白皮書 勤業眾信聯合會計師事務所(2017 ),2017 新藥研發與併購整合白皮書。 勤業眾信聯合會計師事務所 (2018),2018 年生技醫療產業展望。 蕭瑞麟(2017),不用數字的研究:質性研究的思辯脈絡。台北:五南。 二、英文部分 Deloitte (2017) , 'A new future for R&D?Measuring the return from pharmaceutical innovation 2017'. Gottinger, H., Umali, C. & Floether, F. (2011), 'Strategic Alliances in Biotechnology & Pharmaceuticals'. New York : Nova Science Publishers Inc Kurz, P. (2016), 'TaiMed Biologics-Initiate at Buy/1H: First-in-class HIV Therapy Launch Imminent .', Citi Research Report. Martin, R. (2016), 'M&A: The One Thing You Need to Get Right. ' Harvard Business Review, the JUNE 2016 issue, 42-48. McGrath, R. (1997), 'A Real Options Logic for Initiating Technology Positioning Investments' The Academy of Management, 22(4), pp. 974-996 Paul, Steven M., et al. (2010), 'How to improve R&D productivity: the pharmaceutical industry's grand challenge.' Nature reviews Drug discovery, 9(3), pp. 203-214. Pfrang, P., Dealhoy, K., Heller, T., & Shah, S. (2017), 'External innovation: How biopharma companies are bolstering R&D pipelines through dealmaking', Deloitte. Piezunka, H. & Dahlander, L. (2014), 'Distant Search, Narrow Attention: How Crowding Alters Organizations' Filtering of Suggestions in Crowdsourcing' Academy of Management Journal, 58(3), pp. 856-880. Reepmeyer, G. (2006), 'Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing'. Amsterdam: Physica. Rigby, D.(2009), 'Winning in Turbulence'. Massachusetts: Harvard Business Review Press. Schulze, U. & Ringel, M. (2013), 'What matters most in commercial success: first-in-class or best-in-class?.' Nature reviews Drug discovery, 12(6), pp.419-420. Tong, T. , Reuer, J. & Peng, M. (2008), ' International Joint Ventures and the Value of Growth Options' The Academy of Management Journal, 51(5), pp. 1014-1029. Trigeorgis , L . (1990), 'Real Options: Managerial Flexibility and Strategy in Resource Allocation '. Cambridge, Massachusetts: The MIT Press. 三、網頁部分 Adams, B. (2019). Biotechs getting bigger in late-stage R&D, leaving Big Pharmas behind: report. 摘自:https://www.fiercebiotech.com/biotech/biotechs-getting-bigger-late-stage-r-d-leaving-big-pharmas-behind-report Carroll, J. (2019). The biotech era in late-stage drug R&D and marketing has arrived.And it looks like it’s here to stay.摘自: https://endpts.com/the-biotech-era-in-late-stage-drug-rd-and-marketing-has-arrived-and-it-looks-like-its-here-to-stay/ Ein(2014),新藥公司的獲利模式:授權金&權利金,股感知識庫。摘自:https://www.stockfeel.com.tw/%E6%8E%88%E6%AC%8A%E9%87%91/ Gilead Official Website:https://www.gilead.com/ Labiotech.eu. (2018). Everything You Need to Know About Biotech Business Models摘自:https://labiotech.eu/features/young-biotech-business-models/ Medivir Official Website:https://www.medivir.com/ Roche Official Website:https://www.roche.com/ Thomson Reuters Cortellis Database (2019) United Nations Programme on HIV/AIDS (UNAIDS) Official Website:https://www.unaids.org/en U.S. Food and Drug Administration (FDA) Official Website:https://www.fda.gov/ ViiV Healthcare Official Website:https://www.viivhealthcare.com/en-gb/ Weinstein,V. (2018). Why Microsoft Is Willing to Pay So Much for GitHub摘自:https://hbr.org/2018/06/why-microsoft-is-willing-to-pay-so-much-for-github 中裕新藥官方網站:http://www.taimedbiologics.com/cht 哈佛商業評論 (2016),完成超完美併購M&A: The One Thing You Need to Get Right,摘自:https://www.hbrtaiwan.com/article_content_AR0003484.html 哈佛商業評論(2016),決定併購價格的關鍵思考,摘自:https://www.hbrtaiwan.com/article_content_AR0003498.html 哈佛商業評論 (2016),併購賽局新教戰守則The New M&A Playbook,摘自:https://www.hbrtaiwan.com/article_content_AR0003511.html 黃日燦(2016),有機成長+併購=成功轉型。哈佛商業評論。摘自:https://www.hbrtaiwan.com/article_content_AR0003497.html?success=Y 智擎生技官方網站:http://www.pharmaengine.com/zh-hant/ 勤業眾信(2018),生技製藥公司跨國交易法律實務指南 - 從授權、併購及資本市場談起。摘自:https://www2.deloitte.com/tw/tc/pages/legal/articles/biotechnology-pharmaceutical-transaction.html# 衛生福利部疾病管制署(2018),後天免疫缺乏症候群,摘自:https://www.cdc.gov.tw/Category/MPage/mOqwmo-IyKx0ouTNWjuSgA 葉常菁(2017),台灣新藥成功商業授權策略與選題方法,工商時報。摘自:https://m.ctee.com.tw/album/c5d403f6-b667-4a30-bbac-751ac36c7370/5781 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72917 | - |
dc.description.abstract | 企業要透過何種策略追求成長甚至是存活,是一道複雜的多重選擇題;其中一個選項即是近年來十分熱門的研究主題:授權交易。過去研究焦點多集中於站在被授權方角度來看,為何要進行以及如何執行授權交易,鮮少有人關注授權方的存在,更遑論針對欲成功對外授權此目標,應首重哪些重要核心概念與策略。因此,本研究預期能透過打破腦內僵局提出具批判思考的問題,提升研究本質的價值,主張唯有問對問題才能依循對的方向進而找到最適當的答案。
本研究乃一質性研究,選定在生技醫藥產業中,有別於其他治療領域,無論是藥物(產品)種類或是整體市場結構匯聚程度已從過去的零星分散,發展至今大致已趨於穩定與集中的人類免疫缺乏病毒(HIV)藥物市場進行分析。故依本論文研究主軸看來,可從HIV藥物市場過去近三十年交易合作歷史脈絡洞察出輾轉曲折、蛛絲馬跡的變化,達到理解歷史,從變化中體會真相的目的,從中獲得真實成功對外授權策略的研究價值。 本研究結論指出三點成功對外授權之核心概念:(1)合作對象:適配最重要;(2)合作內容:利基性選題將能為中小企業提升對外授權的成功率;以及(3)合作時機:少數企業建立市場主導性之際,是出售產品的最佳時機。而如何將上述核心概念轉換成可執行的策略,以求真正的成功呢?首先,應透過利基性選題,創造新的市場優勢與規模;其次,積極找出差異化,目標成為某個區隔的獨佔者;最後,改變競爭態勢,成為國際藥廠的好夥伴。本研究除豐富對HIV藥物市場的瞭解外,對於成功對外授權的核心策略與邏輯思維,應能提供重要的研究意涵。 | zh_TW |
dc.description.abstract | Adopting a specific strategy to pursue survival or even success is the multiple choice questions encountering by contemporary enterprises. With all of these uncertainties, licensing deal is one of the favorite strategic in recent years. However, previous studies stood on the viewpoint of licensee instead of the role of the licensor and focused only on why and how to proceed with those tedious trading process. Under such circumstance, the core concept of licensing as well as the way of approaching/ selecting the potential buyers usually neglected, not even to mention reaching a successful deal. Thus, weighing on critical thinking during the process of licensing deal shall elevate the application value of the present research. In that aspect, I now assert that only asking the right questions and tracking the precise routes can lead to a proper solution.
The present study adopted the qualitative approaches focusing on the Biopharma industry, especially in the field of HIV pharmaceutical market. Apart from the other regime of drug developing histories, the consolidated HIV market represents its integrity as well as the richness of trading events which can be serving as the best study case regarding its trading licensing deals. With a more than thirty-year trading history in the HIV pharmaceutical sector, those Biopharma are no longer in a sporadic fashion constituting by several small companies. Instead, it has merged into a few giants allowing one to observe how the deal made and to follow what the strategies used at each specific historical time point. Through the story of HIV Biopharma development, it reveals the actual value of licensing deal and further insights on the impacts and successes of those leading giants nowadays. The present study concludes three critical points as follows: (1) the partnership of collaboration: matching is the uttermost; (2) the content of cooperation: picking a niche-type topic brings profit to the SME; (3) the timing of collaboration: best timing of selling leads the leading dominant formation. However, how to convert the above concepts and take into actions for success? First, one shall choose the niche-type topic to create a prominent dominance and growth, but not scaling, in that new market. Second, establishing the mindset to differentiate the markets actively, one will have a chance to become the monopolist. Last, changing the competitive status to the partnership of the international pharmaceutical company. In sum, the present study not only profiled the HIV pharmaceutic market via understanding its developing history but also provided the strategic concept and logical thinking in regards to how to make a successful licensing. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:10:17Z (GMT). No. of bitstreams: 1 ntu-108-P06E43018-1.pdf: 3060294 bytes, checksum: 3db69bfff31968f53061f63ae54fade2 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii ABSTRACT iv 目錄 vi 圖目錄 viii 表目錄 x 第一章 緒論 1 第一節. 研究動機 1 第二節. 研究目的與預期成效 2 第三節. 論文結構 4 第二章 文獻回顧 5 第一節. 理論脈絡與佈局 5 第二節. 「過去」針對授權交易合作相關文獻觀點 5 第三節. 「現在」與本研究假說相關文獻觀點 8 第四節. 「未來」本研究主張之「合」的觀點 12 第三章 研究方法 14 第一節. 理論取樣與個案選擇 14 第二節. 分析架構 18 第三節. 資料收集 19 第四節. 資料分析與研究 20 第四章 研究發現 22 第一節. 人類免疫缺乏病毒藥物市場 22 第二節. HIV藥物市場授權合作交易量化分析與內涵 32 第三節. 三種層次的個案研究與分析 47 第五章 結論與建議 62 第一節. 研究結論 62 第二節. 研究建議 63 第三節. 後續研究方向與建議 65 參考文獻 66 | |
dc.language.iso | zh-TW | |
dc.title | 授權交易之賣方策略研究:以人類免疫缺乏病毒藥物市場為例 | zh_TW |
dc.title | A study of licensing strategies from a licensor's perspective:The case of the HIV pharmaceutical market | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 梅雅俊(Yaa-Jyuhn Meir),陳聿宏(Yu-Hung Chen) | |
dc.subject.keyword | 利基性選題,授權策略,授權交易,人類免疫缺乏病毒藥物,質性研究, | zh_TW |
dc.subject.keyword | The Niche-type topic,Strategy of License,Licensing deal,HIV (Human Immunodeficiency Virus),qualitative methods, | en |
dc.relation.page | 69 | |
dc.identifier.doi | 10.6342/NTU201901763 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-22 | |
dc.contributor.author-college | 進修推廣學院 | zh_TW |
dc.contributor.author-dept | 生物科技管理碩士在職學位學程 | zh_TW |
顯示於系所單位: | 生物科技管理碩士在職學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.99 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。